Orthofix Medical Inc.

NASDAQ:OFIX

Medical - Devices

Healthcare
$6.61 +0.33%

+$0.03 today

Market cap
$269.42M
Beta
0.71
P/E (TTM)
-6.2
EPS (TTM)
-$1.48
52W Low $9.12High $16.99

Volume 0.40M

Average 0.38M

OFIX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Orthofix Medical Inc.NASDAQ: OFIX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $15.32M fell 22.5% year over year, behind the -16.9% change in trailing-twelve-month research & development. Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at +5.2% a year.

Context

  • Research & development amounted to 6.9% of revenue in FY2025, down 2.3 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -22.5% toward the trailing-twelve-month pace of -16.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.32M-0.3% QoQ
Last fiscal yearDec 2025
$57.11M-22.4% YoY
LTMMar 2026
$61.4M-16.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.5%——
1 year-22.4%——
3-year CAGR+5.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
57.11M USD
Year-over-year change
-22.4%
4-year CAGR
+3.6%

Research & Development vs competitors

How OFIX compares with its peers on the latest reported figures

  • OFIX's LTM Mar 2026 research & development of $61.4M is the 5th highest of the 11 companies compared; the peer median is $40.08M.
  • Its year-over-year change of -16.9% is the 8th highest of 11, against a peer median of -2.7%.
  • Research & development amounts to 7.4% of revenue for OFIX, versus a peer median of 26.1%.
OFIX Competitors Peer median
Research & Development for OFIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$220.82M +62.1%+69.0%—
VREXVarex Imaging CorporationLTM Apr 2026$89.5M +0.1%+5.8%10.4%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$87.86M -27.1%-20.4%54.9%
ABSIAbsci CorporationLTM Mar 2026$84.33M +24.0%+11.4%4593.1%
OFIXOrthofix Medical Inc.LTM Mar 2026$61.4M -16.9%+5.2%7.4%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$44.28M -2.4%-26.2%10.6%
BFLYButterfly Network, Inc.LTM Mar 2026$35.88M -3.0%-25.6%34.9%
AVNSAvanos Medical, Inc.LTM Mar 2026$22.9M -6.9%-8.9%3.2%
LABStandard BioTools Inc.LTM Mar 2026$22.48M -43.6%-11.4%26.1%
SIBNSI-BONE, Inc.LTM Mar 2026$17.11M +2.1%+8.6%8.3%
DRIODarioHealth Corp.LTM Mar 2026$12.07M -44.2%-11.1%56.9%
Peer median (excluding OFIX) $40.08M-2.7%-10.0%26.1%

Competitors are the stored peer set for OFIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue464.48M460.71M746.64M799.49M822.31M
Cost of Revenue114.91M123.54M260.37M253.61M270.61M
Gross Profit349.57M337.17M486.27M545.89M551.71M
Gross Margin75.3%73.2%65.1%68.3%67.1%
Research & Development49.62M49.07M80.23M73.64M57.11M
Selling, General & Admin290.67M308.78M530.4M532.53M456.39M
Operating Expenses357.88M350.44M625.38M630.5M620.18M
Depreciation & Amortization33.1M32.08M60.56M60.06M50.97M
EBITDA21.44M15.66M(79.49M)(34.18M)(22.35M)
EBITDA Margin4.6%3.4%-10.6%-4.3%-2.7%
Operating Income(8.32M)(13.27M)(139.11M)(84.62M)(68.47M)
Operating Margin-1.8%-2.9%-18.6%-10.6%-8.3%
Interest Income00000
Interest Expense1.84M1.29M8.63M29.63M17.49M
Other Income / Expenses(5.18M)(4.44M)(9.57M)(39.26M)(22.34M)
Income Before Tax(13.5M)(17.71M)(148.68M)(123.88M)(90.81M)
Pre-Tax Margin-2.9%-3.8%-19.9%-15.5%-11.0%
Income Tax Expense24.88M2.04M2.72M2.12M1.38M
Net Income(38.38M)(19.75M)(151.4M)(126M)(92.19M)
Net Margin-8.3%-4.3%-20.3%-15.8%-11.2%
EPS (Basic)(1.95)(0.98)(4.12)(3.30)(2.28)
EPS (Diluted)(1.95)(0.98)(4.12)(3.30)(2.28)
Weighted Avg Shares19.69M20.1M36.73M38.13M39.88M
Weighted Avg Shares (Diluted)19.69M20.1M36.73M38.13M39.88M

Orthofix Medical Inc.

NASDAQ:OFIX

Intrinsic Alpha fair value

Locked

Current Price

$6.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.